Grunenthal GmbH-Strategic SWOT Analysis Review

Grunenthal GmbH-Strategic SWOT Analysis Review


  • Products Id :- GDPH132572SA
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Grunenthal GmbH-Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-GlobalData's summarization of the company's business strategy.

SWOT analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list of key locations and subsidiaries of the company, including contact details.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Highlights

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. The company researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. It provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal focuses on discovering new methods to treat pain and developing new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Australia, Latin America and the US. It has production plants in Germany, Italy, Switzerland and Ecuador. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH Key Recent Developments

Jul 07,2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)

May 23,2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects

May 10,2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward

May 09,2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal

May 03,2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients

Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Grunenthal GmbH-Key Facts 5

Grunenthal GmbH-Key Employees 6

Grunenthal GmbH-Key Employee Biographies 7

Grunenthal GmbH-Major Products and Services 8

Grunenthal GmbH-History 9

Grunenthal GmbH-Company Statement 10

Grunenthal GmbH-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 14

Grunenthal GmbH-Business Description 14

Grunenthal GmbH-Corporate Strategy 15

Grunenthal GmbH-SWOT Analysis 16

SWOT Analysis-Overview 16

Grunenthal GmbH-Strengths 16

Grunenthal GmbH-Weaknesses 17

Grunenthal GmbH-Opportunities 18

Grunenthal GmbH-Threats 19

Grunenthal GmbH-Key Competitors 20

Section 3-Company's Lifesciences Financial Deals and Alliances 21

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 22

Grunenthal GmbH, Recent Deals Summary 23

Section 4-Company's Recent Developments 24

Jul 07, 2017: Grunenthal Group: Launch of the Project-Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 24

May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives-EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 25

May 10, 2017: Grunenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 26

May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 27

May 03, 2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients 28

Oct 04, 2016: Gabriel Baertschi Takes Office as New CEO of Grunenthal Group as of October 1, 2016 29

Sep 27, 2016: A Research Consortium Under the Direction of Grunenthal Will Receive a Grant of EUR1.5 million From the European Fund for Regional Development and the Federal State of North Rhein-Westphalia 30

Jun 23, 2016: EFIC-Grunenthal Grant 2016 32

Jun 07, 2016: Grunenthal Appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer Effective October 1, 2016 33

Mar 03, 2016: Drug Discovery Collaboration between Grunenthal and Axxam 34

Section 5-Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 22

List of Tables

Grunenthal GmbH, Key Facts 5

Grunenthal GmbH, Key Employees 6

Grunenthal GmbH, Key Employee Biographies 7

Grunenthal GmbH, Major Products and Services 8

Grunenthal GmbH, History 9

Grunenthal GmbH, Other Locations 11

Grunenthal GmbH, Subsidiaries 11

Grunenthal GmbH, Key Competitors 20

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 22

Grunenthal GmbH, Recent Deals Summary 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Grunenthal GmbH, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Overview, Key Manufacturing Facilities, Key Information, Overview, Business Description, Major Products and Services, Brands, History, Key Employees, Key Employee Biographies, Key Operational Heads, Locations And Subsidiaries, Competitors, Company Statement.

select a license
Single User License
USD 125 INR 8873
Site License
USD 250 INR 17745
Corporate User License
USD 375 INR 26618

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com